Dovato is the Brand name for the combination of two medications, such as dolutegravir and lamivudine. The US Food And Drugs Administration (FDA) has approved the treatment of HIV infection based on two drugs and a Single tablet Regime (STR).
It is used to control HIV infection. It helps reduce the amount of HIV in your body so that your immune system can function better. This reduces the likelihood of complications of HIV (for example, new infections, cancer) and improves the quality of life.
The drug Dovato, marketed by GlaxoSmithKline (GSK), has been reported as a complete regimen for the treatment of HIV-1 infection in adult patients with no history of antiretroviral treatment and no known or suspected substitutions associated with resistance to either dolutegravir or lamivudine.
Dolutegravir is an antiretroviral agent for HIV-1. It inhibits the integrase of HIV by binding to the active site and blocking the step of transferring the retroviral DNA integration filament into the host cell. The filament transfer phase is essential in the HIV replication cycle and leads to the inhibition of virus activity.
Lamivudine is a synthetic nucleoside analog and is intracellular phosphorylated to its active metabolite, lamivudine triphosphate (L-TP), 5′-triphosphate. This nucleoside analog is incorporated into the viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in the termination of the DNA chain.
The most common side effects with Dovato were
Less common side effects (Occurred in less than 2% People) of Dovato includes;
Note: This is not a complete list of side effects. You may experience other side effects, consult your doctor.
All patients infected with HIV-1 should be tested for HBV before or at the beginning of Dovato treatment. The appearance of lamivudine-resistant HBV variants associated with antiretroviral therapies containing lamivudine has been reported. If Dovato is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for the appropriate treatment of chronic HBV. Otherwise, consider a different treatment scheme. Serious acute exacerbations of HBV have been reported in patients coinfected with HIV-1 and HBV who discontinued lamivudine, a component of Dovato. Monitor liver functions accurately in these patients and starts anti-HBV therapy if necessary.
Before taking this medicine, tell your health care provider if you
It is contraindicated in the following conditions
As there is a known risk for neural tube defects with dolutegravir, patients are advised to avoid the use of Dovato at the time of conception through the first trimester of pregnancy. Also, It is not recommended for use in breastfeeding women.
Dovato should not be used with the following drugs and conditions. These drugs may increase or decrease the concentration of Dovato which may lead to side effects.
This is not a complete list of drugs. You can consult your doctor before using Dovato along with other drugs.
It is a single tablet and containing two drugs dolutegravir 50 mg and lamivudine 300 mg. It is a once-daily regime. You should take it with or without food.
Dovato has been shown to be effective in clinical trials when the treatment has maintained low levels of HIV RNA (less than 50 copies/ml) in the blood for at least 48 weeks.
The approval was based on Gemini I and II involving more than 1,400 HIV-1 infected patients. This shows that Dovato is as effective as the standard three-drug regimen.
Reduces ARV exposure from the start of treatment while maintaining the efficacy and high barrier to resistance of a conventional three-dolutegravir drug.
1. What is Dovato?
Dovato is the combination of two drugs like dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg. It is used for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC.
2. What is Dovato Used to Treat?
Dovato is a complete regimen for the treatment of HIV-1 infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to either dolutegravir or lamivudine.
3. What are the side effects of Dovato?
The most common side effects associated with the use of this medicine was Nausea, vomiting, Fatigue, headache, insomnia, Diarrhea, etc.
4. What is the dose of Dovato?
Dovato is a once-daily, single-tablet, two-drug regimen that combines the dolutegravir 50 mg with the lamivudine 300 mg. Take it as prescribed by your healthcare practitioner. You can take it with or without food.
5. What happens if I overdose on Dovato?
There is no known specific treatment for overdose. In case of overdose,
The patient should be supervised and standard supportive care provided as needed.
6. Is Dovato safe to use during pregnancy?
Patients are advised to avoid the use of Dovato at the time of conception through the first trimester of pregnancy. Because of dolutegravir in this drug cause neural tube defects.
7. Is Dovato safe to use while Breastfeeding?
No, Breastfeeding is not recommended due to the potential for HIV-1 transmission.
8. How should I take Dovato?
Dovato is a two-drug regimen that combines the dolutegravir 50 mg with the lamivudine 300 mg. It is a once-daily, single-tablet. Take this tablet one time a day exactly as your doctor tells you. You can Take It with or without food.
9. What should I do if I miss a dose of dovato?
If you miss a dose of this medicine, take the missed dose as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and take your next dose at the usual time. Do not take two doses at a time to make up for the missed dose.
10. Who should not take Dovato?
You should not take this medicine if are allergic to it or to any other ingredients present in this formulation. Also, you should avoid taking this medication if you are already taking dofetilide.
11. What are the active ingredients in Dovato?
Dovato is the combination of two active ingredients such as dolutegravir and lamivudine. The inactive ingredients used in Dovato are magnesium stearate, sodium stearyl fumarate, microcrystalline cellulose, mannitol, povidone K29/32, sodium starch glycolate.
12. How to store Dovato?
Keep Dovato in the container and keep the container tightly closed. Do not use it if the original seal covering the opening of the container is broken or missing. Store it at a temperature below 30 ° C (86 ° F).
FDA approves the first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment [Internet]. [Cited 9 April 2019]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-two-drug-complete-regimen-hiv-infected-patients-who-have-never-received
Does the HairMax help you regrow your hair? Read our "HairMax Laserband 82 Review" for… Read More
In this "Prevagen Review" we will see what actually is Prevagen, it's ingredients, Pros &… Read More
In this Folliboost hair growth serum review, we will take a closer look at this… Read More
In this Juvetress Revitalizing Hair Therapy Review, we’re taking an in-depth look into the formula and… Read More
Does Capillus Cap help you regrow your hair? Read our Capillus Laser Cap Review for… Read More